The activin E mechanism of action in obesity is having something of an early stage heyday with such players as Wave Life ...

Dexcom Inc. executives may have thought a $30 million beat of the consensus estimates for third quarter revenue and 20% growth year-over-year provided a treat to shareholders, but investors seemed to ...

Scientists in the U.K. are developing glucose-powered bioelectronics to advance the use and capabilities of implantable medical devices. A research team, led by the University of Bath, received £2.1 ...

Two in five preclinical studies on subarachnoid hemorrhage (SAH) published in peer-reviewed scientific journals contain problematic images. A team of researchers from Radboud University Medical Center ...

Vera Therapeutics Inc.’s atacicept gained still more airtime at the Cantor Fitgerald health care conference held Sept. 4, and some on Wall Street believe the appetite for the BAFF and APRIL dual ...

E and INHBE-targeting WVE-007, a GalNAc-siRNA therapy for obesity. The phase I study called Inlight turned up potent, durable, and dose-dependent activin E reductions with single doses of WVE-007 in ...

Boehringer Ingelheim GmbH has licensed an unnamed small-molecule preclinical candidate from Kyowa Kirin Co. Ltd. in the autoimmune disease space in a deal worth up to €640 million (US$739 million).

University of Eastern Finland has synthesized carbonic anhydrase II (CA2) inhibitors and melanin ligands. As such, they are described as potentially useful for the treatment of glaucoma, macular edema ...

At the AACR-NCI-ORTC conference, researchers from Dewpoint Therapeutics Inc. presented advances in targeting MYC condensates, revealing a potential breakthrough strategy for treating cancers driven by ...

With a modest $7 million up front but an ultimate payout potentially topping $1 billion on the line, Modex Therapeutics Inc.

ALX Oncology Inc. has developed ALX-2004, an antibody-drug conjugate (ADC) targeting epidermal growth factor receptor (EGFR) ...

Lumosa Therapeutics Co. Ltd.’s intravenous odatroltide (LT-3001) met the primary endpoints in a phase IIb trial in China in ...